Skip to main content

Peer Review reports

From: A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer

Original Submission
13 Sep 2016 Submitted Original manuscript
20 Mar 2017 Author responded Author comments - Kerry Lynn Reynolds
12 Feb 2017 Reviewed Reviewer Report - Yingyong Hou
8 Feb 2017 Reviewed Reviewer Report - Peter Muscarella
19 Feb 2017 Reviewed Reviewer Report - Shunji Takahashi
Resubmission - Version 2
20 Mar 2017 Submitted Manuscript version 2
30 Aug 2017 Author responded Author comments - Kerry Lynn Reynolds
16 Jul 2017 Reviewed Reviewer Report - Shunji Takahashi
Resubmission - Version 3
30 Aug 2017 Submitted Manuscript version 3
Publishing
4 Sep 2017 Editorially accepted
12 Sep 2017 Article published 10.1186/s12885-017-3641-6

You can find further information about peer review here.

Back to article page
\